CClinicalTrials.gg
RecruitingNCT05695131Updated May 12, 2026

Clinical Feasibility & Validation of the Virtual Reality GlenxRose Speech-Language Therapies

An interventional study of GlenXRose Virtual Reality Speech Therapies in Vocal Cord Dysfunction and Speech Disorders, sponsored by University of Alberta. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by University of Alberta · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Factors related to successful rehabilitation are often directly related to adherence; for instance, dosage, frequency, and intensity can burden the patient regarding time and motivational factors. Furthermore, surrounding salience, patients may lose interest or find an intervention boring after a few sessions. It is well documented that nonadherence not only impacts rehabilitation for the patient but can also further prolong treatment, and increase hospital and clinician costs, in addition to a higher prevalence of future comorbidities. Therefore, strategies that improve patient adherence can significantly help optimize patient care and treatment outcomes.

One avenue to increase patient adherence is through the gamification of rehabilitation therapies using virtual reality (VR). Gamification of rehabilitation therapy can make mass practice required in rehabilitation therapies seemingly fun and more personally engaging for the patient. Additionally, the immersive experience achieved through VR can further promote salience and be customizable to individual patient requirements. As VR systems are now highly portable and relatively simple to utilize, they can provide an excellent opportunity to continue rehabilitation practice on the home front. Overall, the VR gamification of rehabilitation may increase adherence by shifting patients' perspectives of therapy as tedious, boring, or a hassle, to a fun and engaging game that ultimately helps their recovery processes.

The GlenXRose VR-delivered speech-language therapies (Cognitive Projections Lab, University of Alberta) have been developed and piloted in collaboration with the Glenrose Rehabilitation Hospital with the overall goal of increasing patient adherence, treatment outcomes, and satisfaction with vocal therapy. The proposed studies are to investigate the feasibility of implementing this technology in routine clinical care (specific to voice disorders), obtaining clinician feedback, examining associated financial costs, and continuing to examine the effect of the GlenXRose VR speech-language therapies on patient adherence and clinical outcomes, compared to traditional clinical care.

Read the detailed description

Nonadherence to Speech-Language rehabilitation can result in suboptimal vocal recovery or compensation methods while impacting the quality of life and further burdening the healthcare system. In addition to traditional face-to-face voice therapy, many patients are further given daily voice exercises to practice at home. It is estimated that 38-74% of patients are nonadherent to voice therapies (Ebersole et al., 2018); with such a large prevalence, opportunities to prevent and mitigate nonadherence to voice therapy can significantly promote clinical/functional outcomes. In a recent meta-analysis, it is reported that methods increasing adherence to speech-language rehabilitation further promote home practice (Bartlett et al., 2022). One identified method of promise includes technological approaches (Bartlett et al., 2022) such as the GlenXRose VR Speech-Language therapies (VR-SLP).

Purpose \& Objective: The GlenXRose VR-SLP program, developed by the Cognitive Projections lab at the University of Alberta in collaboration with the Glenrose Rehabilitation Hospital, provides patients with gamified vocal exercises, therapies, and education delivered through immersive virtual reality. With the degree of VR portability, patients will be able to take the equipment home to facilitate at-home vocal practice.

The objective of these studies is to examine the feasibility of implementing the previously developed GlenXRose VR Speech Language therapies (VR-SLP) to routine clinical care delivered by Speech-Language Pathologists to patients with vocal cord disorders. The variables of patient adherence to treatment as well as preliminary effects on vocal measurements (Voice Handicapped Index - 10; Acoustic Analysis of Voice) will be explored.

02

Conditions studied

  • Vocal Cord Dysfunction
  • Speech Disorders

Keywords

  • Vocal
  • Speech
  • Speech-Language Pathology
  • Virtual Reality
  • VR
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults receiving speech-language therapy at the Glenrose Rehabilitation Hospital (Edmonton, AB, Canada; Alberta Health Services)
  • Presence of a speech disorder
  • Proficiency in English
  • Able to provide signed informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairments and/or behavioural impairments
  • Communication disorders that impact comprehension of verbal commands and understanding of scale used in the study
  • Previous history of neurological or psychiatric disorder
  • Substance use disorders
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Virtual Reality Delivered Therapy + Standard Clinical Care

    The GlenXRose virtual reality therapies will be delivered to participants using a head-mounted device to allow vocal therapy and practice. Participants will also receive routine clinical care provided by speech-language pathologists.

    Device: GlenXRose Virtual Reality Speech Therapies

  • No intervention
    Standard Clinical Care

    Participants will receive routine clinical care provided by speech-language pathologists.

Interventions

  • DeviceGlenXRose Virtual Reality Speech Therapies

    Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations

05

What researchers measure

Primary outcomes

  1. Change in Frequency and Treatment Adherence Rates

    Reported Frequency of Rehabilitation Therapy

    Time frame: Up to 12 Weeks

  2. Change in Generalization

    Self-reported time using voice production techniques

    Time frame: Up to 12 Weeks

  3. Change in Compliance Rate

    Self-reported time (using a visual analog scale)

    Time frame: Up to 12 Weeks

  4. Change in Voice Handicap Index - 10

    Quantification of participant reported perspectives of voice impairment(s)

    Time frame: Up to 12 Weeks

  5. Change in Acoustic Analysis of Voice

    Conducted by Registered Speech-Language Pathologists (as part of standard care)

    Time frame: Up to 12 Weeks

06

Study locations

1 of 1 sites recruiting
07

References and documents

Publications

  • Rosen CA, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the voice handicap index-10. Laryngoscope. 2004 Sep;114(9):1549-56. doi: 10.1097/00005537-200409000-00009. PubMed 15475780 ↗
  • Bartlett RS, Carpenter AM, Chapman LK. A Systematic Review of Adherence Strategies for Adult Populations in Speech-Language Pathology Treatment. Am J Speech Lang Pathol. 2022 May 10;31(3):1501-1516. doi: 10.1044/2022_AJSLP-21-00255. Epub 2022 Mar 23. PubMed 35320678 ↗
  • Ebersole B, Soni RS, Moran K, Lango M, Devarajan K, Jamal N. The Role of Occupational Voice Demand and Patient-Rated Impairment in Predicting Voice Therapy Adherence. J Voice. 2018 May;32(3):325-331. doi: 10.1016/j.jvoice.2017.06.002. Epub 2017 Jul 11. PubMed 28709763 ↗
  • Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasibility Stud. 2016 Oct 21;2:64. doi: 10.1186/s40814-016-0105-8. eCollection 2016. PubMed 27965879 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT05695131
Lead sponsor
University of Alberta
Collaborators
Alberta Health services
Responsible party
Sponsor
First posted
Jan 23, 2023
Start date
Sep 20, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
May 12, 2026

Study contacts

Adriana Rios Rincon, PhD, R.OT
Contact
aros@ualberta.ca
780.492.5150
Mathieu Figeys, PhD, RN
Contact
figeys@ualberta.ca
780.735.6296
Adriana Rios Rincon, PhD, R.OT
principal investigator · University of Alberta
Antonio Miguel Cruz, DrSc
study chair · University of Alberta
James Raso, MASc
study chair · Glenrose Rehabilitation Hospital, Alberta Health Services

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion